DSP Healthcare Fund Regular-Growth
The fund is rated 4 stars. The strongest areas were investment selection within each asset type and investment selection within each industry, while balance between returns and downside risk provided some support. Higher annual fee of 2.05% and above-average fund size of Rs 3,835.28 crore were minor drawbacks.
This fund has a good track record with Asset Selection/Timing, a good track record with Stock Selection/Timing. It is important to note, however, that this fund has a 3835.275 AUM and a 2.05 expense ratio. Considering all these factors, we have rated this fund as 4.0 star.
અમારો સ્કોર લાંબા ગાળાની કામગીરી, જોખમ અને સાતત્યને વજન આપે છે — ફક્ત ભૂતકાળના વળતરને નહીં.
રિટર્ન
7 Oct 2026 મુજબ
જોખમ ગુણોત્તર
30 Sep 2026 મુજબ
પોર્ટફોલિયો
31 Aug 2026 મુજબ
માર્કેટ-કેપ વિભાજન
સેક્ટર ફાળવણી
હોલ્ડિંગ્સ (32)
| હોલ્ડિંગ | ફંડનો % | મૂલ્ય | શેર |
|---|---|---|---|
| Ipca Laboratories Ltd. | 8.74% | ₹335.02 Cr | 16,96,381 |
| Sun Pharmaceutical Industries Ltd. | 7.95% | ₹304.78 Cr | 15,35,592 |
| Sai Life Sciences Ltd. | 7.45% | ₹285.72 Cr | 19,57,356 |
| Cipla Ltd. | 7.35% | ₹282.03 Cr | 20,01,379 |
| Apollo Hospitals Enterprise Ltd. | 6.47% | ₹248.03 Cr | 2,78,729 |
| Gland Pharma Ltd. | 5.98% | ₹229.5 Cr | 7,95,267 |
| Globus Medical Inc | 5.44% | ₹208.77 Cr | 2,68,800 |
| Divi's Laboratories Ltd. | 4.15% | ₹159.26 Cr | 1,68,223 |
| Alkem Laboratories Ltd. | 4.08% | ₹156.61 Cr | 2,93,861 |
| Cohance Lifesciences Ltd. | 3.81% | ₹146.04 Cr | 32,02,999 |
ફંડ વિગતો
Long term capital growth. Investment in equity and equity related Securities of healthcare and pharmaceutical companies/entities.
The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies/entities.
Exit load of 0.50% if redeemed within 1 month.